Page 25 - 2021_10-Haematologica-web

Dose intensity for induction in AML
prognostic factors. J Clin Oncol. 2010;28
(4):549-555.
56. Burnett AK, Russell NH, Kell J, et al.
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol. 2010;28(14):2389-2395.
57. Foran JM, Sun ZX, Claxton DF, et al. North American Leukemia Intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age >= 60 years): a trial of the ECOG-ACRIN Cancer Research Group (E2906). Blood. 2015;126(23):217.
58. Burnett AK, Russell NH, Hills RK, et al. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induc- tion treatment in older patients with acute myeloid leukaemia. Leukemia. 2017;31(2): 310-317.
59.Bouabdallah R, Lefrere F, Rose C, et al. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk eld- erly patients. Leukemia. 1999;13(10):1491- 1496.
60. Huang BT, Zhao WH, Zeng QC, Li BS, Chen RL. Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in eld- erly patients with acute myeloid leukemia. Med Oncol. 2014;31(5):962.
61. Liu H, Fu R, Li L, et al. Comparison of reduced-intensity idarubicin and daunoru- bicin plus cytarabine as induction chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia. Clin Drug Investig. 2017;37(2):167-174.
62. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114-1124.
63.Savona MR, Pollyea DA, Stock W, et al. Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. Clin Cancer Res. 2018;24(10):2294-2303.
64. Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytara- bine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syn- drome. Leukemia. 2019;33(2): 379-389.
65. Talati C, Goldberg AD, Przespolewski A, et al. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leuk Res. 2020;93:106367.
66.Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291-299.
67. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with inten- sive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120(24):4840-4845.
68. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open- label, phase III trial of decitabine versus patient choice, with physician advice, of
either supportive care or low-dose cytara- bine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677.
69.Visani G, Ferrara F, Di Raimondo F, et al. Low-dose lenalidomide plus cytarabine induce complete remission that can be pre- dicted by genetic profiling in elderly acute myeloid leukemia patients. Leukemia. 2014;28(4):967-970.
70. Visani G, Ferrar F, Di Raimondo F, et al. Low- dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: final result of a phase II study. Leukemia Res. 2017;62:77-83.
71.DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17.
72. Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax combined with low-dose cytara- bine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15): 1277-1284.
73. Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137-2145.
74. Kadia TM, Cortes J, Ravandi F, et al. Cladribine and low-dose cytarabine alter- nating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018;5(9):e411-e421.
75. Kadia TM, Borthakur G, Pemmaraju N, et al. Phase II study of venetoclax added to cladribine plus low dose AraC (LDAC) alter- nating with 5-azacytidine demonstrates high rates of minimal residual disease (MRD) negative complete remissions (CR) and excellent tolerability in older patients with newly diagnosed acute myeloid leukemia (AML). Blood. 2020;136(Suppl 1):17-19.
76. Chua CC, Roberts AW, Reynolds J, et al. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol. 2020;38(30): 3506-3517.
77. Aboudalle I, Konopleva MY, Kadia TM, et al. A phase Ib/II study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction/consolidation ther- apy with FLAG-IDA in patients with newly diagnosed or relapsed/refractory AML. Blood. 2019;134(Suppl 1):176.
78. Kadia TM, Garcia-Manero G, Yilmaz M, et al. Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable com- plete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol. 2020;38(15-suppl): 7539.
79. Prassek VV, Rothenberg-Thurley M, Sauerland MC, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018;103(11):1853-1861.
80. Wetzler M, Mrozek K, Kohlschmidt J, et al. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of kary- otype and selected molecular markers used in the European LeukemiaNet classification.
Haematologica. 2014;99(2):308-313. 81.Mrozek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alter- ations in adults with acute myeloid leukemia.
J Clin Oncol. 2012;30(36):4515-4523.
82. Daver N, Liu Dumlao T, Ravandi F, et al. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma
Leuk. 2013;13(4):435-440.
83. Ravandi F, Issa JP, Garcia-Manero G, et al.
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnor- malities. Cancer. 2009;115(24):5746-5751.
84. Seymour JF, Dohner H, Butrym A, et al. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes com- pared with conventional care regimens. BMC Cancer. 2017;17(1):852.
85. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-569.
86. Breems DA, Lowenberg B. Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spec- trum. Haematologica. 2011;96(4):491-493.
87. Becker H, Pfeifer D, Ihorst G, et al. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine- treated patients with acute myeloid leukemia. Ann Hematol. 2020;99(7):1551- 1560.
88. Breems DA, Van Putten WL, Lowenberg B. The impact of abn(17p) and monosomy - 5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia. Blood. 2013;121(15):3056-3057.
89. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
90.Kadia TM, Jain P, Ravandi F, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular charac- teristics, response to therapy, and outcomes. Cancer. 2016;122(22):3484-3491.
91.Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with spe- cific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114-2121.
92.Boddu P, Kantarjian H, Ravandi F, et al. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma. 2018;59(9):2238-2241.
93.Cluzeau T, Sebert M, Rahmé R, et al. Eprenetapopt plus azacitidine in TP53- mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol. 2021;39(14):1575-1583.
94. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322-3327.
95. Gupta N, Miller A, Gandhi S, et al. Comparison of epigenetic versus standard induction chemotherapy for newly diag- nosed acute myeloid leukemia patients
haematologica | 2021; 106(10)
2553